未经证实：在HBV感染者中，只有一部分慢性肝炎患者需要治疗，这个比例因人口而异，区域,和设置。没有估计感染HBV并符合法国治疗资格标准的人的比例。
UNASSIGNED：552治疗初治的慢性HBV感染的个体首次提到2008年至2012年之间的肝病参考中心被前瞻性地包括在内。人口统计,临床,并对实验室数据进行了分析。
未经批准：总共，61.1%的患者为男性,平均年龄为37.5岁。此外，64％出生在中间或高流行的HBV国家，90%为HBeAg阴性。在转诊时，中位HBVDNA和HBsAg水平为3.3和3.6logIU/ml，分别为37.8%的患者谷丙转氨酶>40U/L,29.0%有中度或重度纤维化（≥F2），包括9.4％的肝硬化。最普遍的基因型是D（34.7％），E（27.4%），和A（25.7%）。合并感染很少见：2.4％为HIV阳性，4.0%为HCV阳性，6.0%为HDV阳性。根据2017年EASL临床实践指南，使用单个时间点分析，2.7％的患者被归类为HBeAg阳性慢性感染，6.1％为HBeAg阳性慢性乙型肝炎，26.5%为HBeAg阴性慢性乙型肝炎，和61.1％作为HBeAg阴性慢性感染，而3.6%的患者无法分类。HBsAg水平定量识别HBeAg阴性慢性乙型肝炎个体的性能较差。共有29.1%符合开始抗病毒治疗的标准,而66.5%仍在常规临床监测中。大多数符合条件的患者开始推荐一线治疗，包括替诺福韦（45.3%），恩替卡韦（36.8%），或聚乙二醇干扰素α（11.6％）。
未经批准：在所有情况下，9.4%的患者出现肝硬化，29.1%的患者符合2017年EASL临床实践指南治疗标准。HBsAg水平未能准确识别HBeAg阴性慢性感染的个体。
UNASSIGNED：在法国成人慢性HBV感染首次提到肝病参考中心，大约三分之一的人患有严重的肝病。大约三分之一的个体符合基于恩替卡韦或替诺福韦的抗病毒治疗的启动标准，偶尔,聚乙二醇干扰素α.
UNASSIGNED: Among people living with HBV, only a subset of individuals with chronic hepatitis is in need of treatment, and this proportion varies according to the population, region, and setting. No estimates of the proportion of people who are infected with HBV and meet the treatment eligibility criteria in France are available.
UNASSIGNED: 552 treatment-naïve individuals with chronic HBV infection referred for the first time to a hepatology reference centre between 2008 and 2012 were prospectively included. Demographic, clinical, and laboratory data were analysed.
UNASSIGNED: In total, 61.1% of patients were males, with a median age of 37.5 years. Moreover, 64% were born in an intermediate- or high-HBV endemicity country, and 90% were HBeAg-negative. At referral, median HBV DNA and HBsAg levels were 3.3 and 3.6 log IU/ml, respectively; 37.8% of patients had alanine aminotransferase >40 U/L, and 29.0% had moderate or severe fibrosis (≥F2), including 9.4% with cirrhosis. The most prevalent genotypes were D (34.7%), E (27.4%), and A (25.7%). Coinfections were rare: 2.4% were HIV-positive, 4.0% were HCV-positive, and 6.0% were HDV-positive. According to the 2017 EASL Clinical Practice Guidelines, using a single time point analysis, 2.7% of patients were classified as HBeAg-positive chronic infection, 6.1% as HBeAg-positive chronic hepatitis B, 26.5% as HBeAg-negative chronic hepatitis B, and 61.1% as HBeAg-negative chronic infection, whereas 3.6% patients could not be classified. The performance of HBsAg level quantification to identify individuals with HBeAg-negative chronic hepatitis B was poor. A total of 29.1% met the criteria for initiation of antiviral treatment, whereas 66.5% remained under routine clinical surveillance. Most eligible patients initiated recommended first-line therapies, including tenofovir (45.3%), entecavir (36.8%), or pegylated interferon alpha (11.6%).
UNASSIGNED: Of all cases, 9.4% had cirrhosis at presentation and 29.1% met the 2017 EASL Clinical Practice Guidelines treatment criteria. HBsAg levels failed to accurately identify individuals with HBeAg-negative chronic infection.
UNASSIGNED: Among French adults chronically infected with HBV referred for the first time to hepatology reference centres, about one-third had a significant liver disease. Approximately one-third of individuals met criteria for initiation of antiviral treatment based on entecavir or tenofovir or, occasionally, pegylated interferon alpha.
PDF(Pubmed)